Zhongguo shi yan xue ye xue za zhi · 2016
[Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of T Cell Lymphoblastic Lymphoma - Clinical observation of 10 Cases].
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gong Fang, Chen Heng, Zhao Lin-Yan, Wang Tong, Zhang Ri, Wu De-Pei
Аннотация
OBJECTIVE: To analyze the result of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treatment of patients with T cell Lymphoblastic lymphoma(T-LBL).
METHODS: The engraftment, graft versus host disease (GVHD), infection, relapse and survival of 10 T-LBL patients received allo-HSCT was observed. The clinical outcome of allo-HSCT for T-LBL patients was analyzed.
RESULTS: The median age of patients was 25 years old, 10 (6 males and 4 females) T-LBL patients received allo-HSCT including 3 from HLA-matched unrelated donors, 3 from HLA-matched sibling donors, 2 from HLA haploidentical sibling donors, and 2 from haploidentical related donors. The clinical staging showed that 1 case was in stage III and 8 cases were in stage IV. The bone marrow was involved in 7 patients. All the 10 patients achieved engraftment, and the median times of neutrophil and platelet engraftment were 11 (10-19) days and 12(7-19) days, respectively. Acute GVHD occurred in 5 patients and chronic GVHD occured in 1 patient. After the median follow-up of 26 months (11-51 months), 3 patients died, out of them 1 died from relapse after transplantation, 1 from infection and 1 from GVHD. The relapse, overall survival, and disease-free survival rate were 10%, 70%, 70%,respectively. And the estimated overall survival rate was 66.7%.
CONCLUSION: T-LBL has high rate of relapse and poor prognosis. The allo-HSCT can improve the survival of patients with T-LBL, and is an effective method for treatment of T-LBL patients.
METHODS: The engraftment, graft versus host disease (GVHD), infection, relapse and survival of 10 T-LBL patients received allo-HSCT was observed. The clinical outcome of allo-HSCT for T-LBL patients was analyzed.
RESULTS: The median age of patients was 25 years old, 10 (6 males and 4 females) T-LBL patients received allo-HSCT including 3 from HLA-matched unrelated donors, 3 from HLA-matched sibling donors, 2 from HLA haploidentical sibling donors, and 2 from haploidentical related donors. The clinical staging showed that 1 case was in stage III and 8 cases were in stage IV. The bone marrow was involved in 7 patients. All the 10 patients achieved engraftment, and the median times of neutrophil and platelet engraftment were 11 (10-19) days and 12(7-19) days, respectively. Acute GVHD occurred in 5 patients and chronic GVHD occured in 1 patient. After the median follow-up of 26 months (11-51 months), 3 patients died, out of them 1 died from relapse after transplantation, 1 from infection and 1 from GVHD. The relapse, overall survival, and disease-free survival rate were 10%, 70%, 70%,respectively. And the estimated overall survival rate was 66.7%.
CONCLUSION: T-LBL has high rate of relapse and poor prognosis. The allo-HSCT can improve the survival of patients with T-LBL, and is an effective method for treatment of T-LBL patients.